Evidence map›Paper›PMID 35236770›Full record

ArticleMolecular pharmacology2022

Effects of Sarcomere Activators and Inhibitors Targeting Myosin Cross-Bridges on Ca

Monika Halas, Paulina Langa, Chad M Warren, Paul H Goldspink, Beata M Wolska, R John Solaro

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Reduction in myofilament CaFrontiers in physiology · 2025
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Monika HalasDepartment of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.) and Department of Medicine, Division of Cardiology (B.M.W.), University of Illinois at Chicago, Chicago, Illinois.
Paulina LangaDepartment of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.) and Department of Medicine, Division of Cardiology (B.M.W.), University of Illinois at Chicago, Chicago, Illinois planga2@uic.edu solarorj@uic.edu.
Chad M WarrenDepartment of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.) and Department of Medicine, Division of Cardiology (B.M.W.), University of Illinois at Chicago, Chicago, Illinois.
Paul H GoldspinkDepartment of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.) and Department of Medicine, Division of Cardiology (B.M.W.), University of Illinois at Chicago, Chicago, Illinois.
Beata M WolskaDepartment of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.) and Department of Medicine, Division of Cardiology (B.M.W.), University of Illinois at Chicago, Chicago, Illinois.
R John SolaroDepartment of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.) and Department of Medicine, Division of Cardiology (B.M.W.), University of Illinois at Chicago, Chicago, Illinois.
University of Illinois Chicago · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN · 2000 to 2020
$42.4M
Myofilament signaling and cardiac disordersR01HL128468 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN, WOLSKA, BEATA M. · 2016 to 2019
$1.6M
NHLBI NIH HHS P01 HL062426NHLBI NIH HHS R01 HL128468
6 · The paper itself

Abstract

We tested the hypothesis that isoform shifts in sarcomeres of the immature heart modify the effect of cardiac myosin-directed sarcomere inhibitors and activators. Omecamtiv mecarbil (OM) activates tension and is in clinical trials for the treatment of adult acute and chronic heart failure. Mavacamten (Mava) inhibits tension and is in clinical trials to relieve hypercontractility and outflow obstruction in advanced genetic hypertrophic cardiomyopathy (HCM), which is often linked to mutations in sarcomeric proteins. To address the effect of these agents in developing sarcomeres, we isolated heart fiber bundles, extracted membranes with Triton X-100, and measured tension developed over a range of Ca

Indexed as

MyofibrilsSarcomeresAnimalsCalciumMiceMice, TransgenicMyocardial ContractionMyocardiumMyocytes, CardiacMyosinsTroponin ICalciumMyosinsTroponin I

Identifiers

PMID35236770
PMCPMC9092471
OpenAlexW4214902276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.